Neonatal Hyperthyroidism: Case Report and Literature Review.

MCN Am J Matern Child NursAug 13, 2026 (epub)
Case ReportEndocrinologyPediatrics

Emily Sowa, Sharon Anderson

✦ AI-curated · Sources linked

Case in brief

A late preterm infant presented with thyrotoxicosis due to maternal Graves disease, which had been treated with radioactive iodine. The infant's condition was linked to the transplacental transfer of thyrotropin receptor antibodies. Early assessment of neonatal thyroid function was crucial for timely intervention, highlighting the need for monitoring in infants born to mothers with a history of Graves disease.

Diagnostic / clinical pearl

Clinicians should assess thyroid function in neonates born to mothers with a history of Graves disease to identify potential hyperthyroidism early.

Why it matters

This case underscores the importance of monitoring maternal thyroid antibodies during pregnancy to prevent neonatal complications.

Source

PubMed · PMID 42160187

Published in MCN Am J Matern Child Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.